{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:15:03Z","timestamp":1770502503083,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2006,9,20]],"date-time":"2006-09-20T00:00:00Z","timestamp":1158710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Although the prognosis of type 1 autoimmune hepatitis is generally good with immunosuppressive treatment, the disease progresses in some patients despite the treatment. The prognosis may be determined by the clinical course.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the long\u2010term prognosis and assess the predictive factors for a serious event, including the development of hepatocellular carcinoma or death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixty\u2010nine patients with type 1 autoimmune hepatitis were prospectively followed up regularly, with a median follow\u2010up period of 96\u2003months (49\u2013201\u2003months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the follow\u2010up period, three patients (4%) developed hepatocellular carcinoma, and two of these three patients died. Another patient died of liver failure. The 10\u2010year survival rate was 98%, and the 10\u2010year hepatocellular carcinoma\u2010free rate was 93%. The four patients experiencing a serious event received higher maintenance doses of corticosteroid during their follow\u2010up periods than those did not. However, serum alanine aminotransferase levels during the follow\u2010up period were higher in these four patients than in the others.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Persistent elevation of serum alanine amniotransferase levels during the follow\u2010up period, rather than factors existing prior to medical treatment is considered to be an important prognostic factor, and it is indicated that poor outcomes may result from the resistance to immunosuppressive treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2006.03113.x","type":"journal-article","created":{"date-parts":[[2006,9,20]],"date-time":"2006-09-20T14:45:16Z","timestamp":1158763516000},"page":"1197-1205","source":"Crossref","is-referenced-by-count":50,"title":["Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis"],"prefix":"10.1111","volume":"24","author":[{"given":"Y.","family":"MIYAKE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"IWASAKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"TERADA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"OKAMAOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"IKEDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"MAKINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"KOBASHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"TAKAGUCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"SAKAGUCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"SHIRATORI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,9,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24227"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.01.009"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8608895"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005638500236"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220305"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.38.422"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200006000-00020"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s005350300034"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200309000-00017"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00311464"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-003-0878-z"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.44.949"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.06.006"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20732"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190629"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80005-4"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30457.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.1999.tb00009.x"},{"key":"e_1_2_6_21_2","first-page":"749","article-title":"Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan","volume":"11","author":"Hino T","year":"2003","journal-title":"Int J Mol Med"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-2472-5"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1998.tb00674.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300603"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.500050106"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2000.7629"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200103000-00013"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011915032118"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34944"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.03113.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.03113.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T07:12:50Z","timestamp":1697181170000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.03113.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,20]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1111\/j.1365-2036.2006.03113.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03113.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,20]]}}}